Marit Scheistrøen
Impact in
- Reproductive Medicine top 5%
- Ovarian cancer diagnosis and treatment
- Obstetrics and Gynecology top 5%
- Endometrial and Cervical Cancer Treatments
Papers in
-
- Endometrial and Cervical Cancer Treatments 5
-
- Ovarian cancer diagnosis and treatment 5
- Co-authors
- Claes G. TropéC. TropéErik O. PettersenVera M. AbelerJahn M. NeslandGunnar B. KristensenAmin MakarD. Van den Weyngaert
In The Last Decade
Marit Scheistrøen
16 papers receiving 387 citations
Peers
Comparison fields: 5 of 46
- Reproductive Medicine 121
- Obstetrics and Gynecology 95
- Dermatology 68
- Oncology 161
- Epidemiology 161
Countries citing papers authored by Marit Scheistrøen
This map shows the geographic impact of Marit Scheistrøen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marit Scheistrøen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marit Scheistrøen more than expected).
Fields of papers citing papers by Marit Scheistrøen
This network shows the impact of papers produced by Marit Scheistrøen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marit Scheistrøen. The network helps show where Marit Scheistrøen may publish in the future.
Co-authors
The 25 scholars most cited alongside Marit Scheistrøen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 17 | |
| 2 | 2005 | 15 | |
| 3 | 2004 | 39 | |
| 4 | 2003 | 21 | |
| 5 | 2003 | 38 | |
| 6 | Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977-1991. | 2002 | 16 |
| 7 | First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial | 2002 | 12 |
| 8 | 2001 | 41 | |
| 9 | [Surgery and sentinel node examination in early vulvar cancer]. | 2001 | 2 |
| 10 | 2001 | 9 | |
| 11 | 1997 | 23 | |
| 12 | 1996 | 21 | |
| 13 | 1995 | 62 | |
| 14 | 1993 | 30 | |
| 15 | 1992 | 50 | |
| 16 | [Laser treatment of premalignant diseases of the uterine cervix. Experiences from a central hospital]. | 1992 | 1 |
About Marit Scheistrøen
Marit Scheistrøen is a scholar working on Obstetrics and Gynecology, Reproductive Medicine, Immunology and Allergy, Oncology and Epidemiology, having authored 16 papers that have together received 397 indexed citations. Recurring topics across this work include Cervical Cancer and HPV Research (6 papers), Endometrial and Cervical Cancer Treatments (5 papers), Ovarian cancer diagnosis and treatment (5 papers), Sarcoma Diagnosis and Treatment (3 papers), Colorectal and Anal Carcinomas (3 papers), Nonmelanoma Skin Cancer Studies (3 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and Blood Coagulation and Thrombosis Mechanisms (2 papers). The work is most often cited by research in Reproductive Medicine (121 citations), Obstetrics and Gynecology (95 citations), Dermatology (68 citations), Oncology (161 citations) and Epidemiology (161 citations). Marit Scheistrøen has collaborated with scholars based in Norway, Belgium and Sweden. Frequent co-authors include Claes G. Tropé, C. Tropé, Erik O. Pettersen, Vera M. Abeler, Jahn M. Nesland, Gunnar B. Kristensen, Amin Makar, D. Van den Weyngaert, Ignace Vergote and J. Kærn. Their work appears in journals such as Gynecologic Oncology, International Journal of Gynecological Cancer, American Journal of Clinical Pathology, Cancer and Acta Oncologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.